Clinical trials · Massachusetts
Glioma clinical trials in Massachusetts
We’re tracking 30 recruiting glioma studies with a site in Massachusetts — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Boston, MassachusettsAges 2–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Boston, MassachusettsAges 1–21 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Boston, MassachusettsAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Boston, MassachusettsAges 1–39 - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Boston, MassachusettsAges 2–21 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Boston, MassachusettsAges 12–39 - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Boston, MassachusettsAges 1–25 - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Boston, MassachusettsAges 1–21 - NCT04135807RecruitingEarly Phase 1
Implantable device test for operable brain tumor patients
This early-phase trial tests a tiny implanted device placed during brain tumor surgery. It delivers very small doses of medicine directly to the tumor area for a short time, aiming to see if this approach is safe and workable in patients with certain gliomas.
Boston, MassachusettsAges 18 years+ - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Boston, MassachusettsAges Up to 21 years - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Boston, MassachusettsAges 1–21 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Boston, MassachusettsAges 16 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Boston, MassachusettsAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
Boston, MassachusettsAges 6 months–25 years - NCT04943848RecruitingPhase 1
Vaccine plus immune treatment for newly diagnosed brain stem tumors
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
Boston, MassachusettsAges 1–18 - NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Boston, MassachusettsAges 3–39 - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Boston, MassachusettsAges Any age - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT06118723Recruiting
Supramaximal vs maximal surgery for brain tumors
This trial compares removing as much tumor as safely possible (supramaximal resection) with standard maximal resection in people with high-grade glioma (an aggressive brain tumor). The goal is to see if more extensive removal improves survival and quality of life.
Boston, MassachusettsAges 18–90 - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Boston, MassachusettsAges 18 years+ - NCT03761121Recruiting
Imaging study for low-grade glioma in children and adults
This study is testing how to take faster, better brain images in people diagnosed with low-grade glioma (a type of brain tumor). Better imaging may help doctors see the tumor more clearly while reducing time spent in the scanner.
Boston, MassachusettsAges birth+ - NCT03922555RecruitingPhase 1
ASTX727 for IDH-mutant low-grade brain tumors
This early-stage study tests ASTX727 in adults with IDH-mutant gliomas that are coming back or progressing. It aims to see whether the medicine can slow the tumor and understand how it works in the body and tumor tissue.
Boston, MassachusettsAges 18 years+ - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Boston, MassachusettsAges 16 years+
Glioma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting glioma studies listed above.
- Dana-Farber Cancer Institute · 19 studies
- Massachusetts General Hospital · 9 studies
- Brigham and Women's Hospital · 4 studies
- Beth Israel Deaconess Medical Center
- Boston Children Hospital
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center
- Mass General Waltham
- Ophthalmic Consultants of Boston
What taking part in a glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioma trials in other states
Common questions
- Are there glioma clinical trials in Massachusetts?
- Yes. We're currently tracking 30 recruiting glioma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.